Related Experiment Video
Updated: Jun 12, 2025
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Michael H Davidson1,2, Andrew Hsieh2, Mary R Dicklin3
1University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
Insights
Cardiovascular drug development faces rising costs and delays, impacting patient access. This paper explores strategies to make cardiovascular outcomes trials more cost-effective, fostering innovation.
Area of Science:
- Pharmacology
- Clinical Trials
- Drug Development
Background:
- Cardiovascular disease (CVD) is a leading global cause of death.
- Therapeutic agents for CVD, like LDL-lowering drugs, are vital.
- Rising development costs and regulatory hurdles limit new cardiovascular (CV) drug approvals.
Purpose of the Study:
- To review potential approaches for enhancing the cost-effectiveness of CV drug development.
- To address the financial burden and lengthy timelines of traditional cardiovascular outcomes trials (CVOTs).
Main Methods:
- Review of existing literature on CV drug development and clinical trial methodologies.
- Analysis of cost-saving strategies applicable to cardiovascular outcomes trials.
Main Results:
- Traditional CVOTs are time-consuming and expensive, delaying drug availability.
- Cost-effective CVOTs are crucial for continued innovation in CV therapeutics.
- Compromised drug innovation due to trial costs negatively impacts CV patients.
Conclusions:
- Implementing cost-effective strategies in CVOTs is essential for pharmaceutical companies.
- Streamlining CVOTs can accelerate patient access to novel cardiovascular medications.
- Addressing the economic challenges in CV drug development is critical to reduce CVD morbidity and mortality.
Abstract:
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Therapeutic agents, such as those that lower low-density lipoprotein cholesterol, have been a critical factor in mitigating CVD event risk and demonstrate the important role that drug discovery plays in reducing morbidity and mortality. However, rapidly rising development costs, diminishing returns, and an increasingly challenging regulatory environment have all contributed to a declining number of cardiovascular (CV) therapeutic agents entering the health care marketplace. For pharmaceutical companies, a traditional cardiovascular outcomes trial (CVOT) can be a major financial burden and impediment to CV agent development. They can take as long as a decade to conduct, delaying potential investment return while carrying risk of failure. For patients, lengthy CVOTs delay drug accessibility. Without cost-effective CVOTs, drug innovation may be compromised, with CV patients bearing the consequences. This paper reviews potential approaches for making CV drug development more cost-effective.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inotropic Agents